Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia
Burosumab, a fully human monoclonal antibody against fibroblast growth factor 23, is mainly administered to patients with severe X-linked hypophosphatemia (XLH). However, there have been few reports on its use in relatively mild cases. In this report, we administered burosumab to two siblings with X...
Gespeichert in:
Veröffentlicht in: | Clinical Pediatric Endocrinology 2024, Vol.33(1), pp.27-34 |
---|---|
Hauptverfasser: | , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 34 |
---|---|
container_issue | 1 |
container_start_page | 27 |
container_title | Clinical Pediatric Endocrinology |
container_volume | 33 |
creator | Senoo, Shintaro Fujimoto, Masanobu Yamaguchi, Yukiko Osaki, Mari Hanaki, Keiichi Namba, Noriyuki |
description | Burosumab, a fully human monoclonal antibody against fibroblast growth factor 23, is mainly administered to patients with severe X-linked hypophosphatemia (XLH). However, there have been few reports on its use in relatively mild cases. In this report, we administered burosumab to two siblings with XLH who had been effectively treated with oral phosphate and active vitamin D. Both patients showed further improvement in radiographic and laboratory findings with burosumab compared with conventional treatment. Upon switching treatment, popliteal pain was reported in case 1 until her phosphorus levels normalized. This emphasizes the importance of monitoring not only rickets and calcium/phosphate metabolism but all symptoms of XLH after initiating burosumab. Notably, in cases 1 and 2, burosumab sustained catch-up growth, especially in case 1, who had not yet reached puberty. Further clinical studies are needed to determine whether burosumab improves growth and proportional abnormalities in patients with mild XLH. |
doi_str_mv | 10.1297/cpe.2023-0043 |
format | Article |
fullrecord | <record><control><sourceid>pubmed_cross</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10825651</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>38299174</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3523-5e1099354e8d86c1343fa59b3d31a60e24fc433b4f670972352499a2790e5af33</originalsourceid><addsrcrecordid>eNpVkc1u1DAUhS0EokPLki3yC6S1feMkXiE04qdSJRZQqTvL8dxMXJw4sj1Tzdvj6cAAG9vS_c6xzj2EvOPsmgvV3tgFrwUTUDFWwwuy4lC3VQuye0lWTPGuki2oC_ImpUfGhGINe00uoBNK8bZekf33J5ft6OYtzYH2uxjSbjI9HWKYqA3zHufswmw8zSNGsxyom2lyvS-KRIt2pBG9yW6P_kCf0PuqqHIM3uOGPlSF-1ke42EJyxjSMpqMkzNX5NVgfMK3v-9Lcv_504_11-ru25fb9ce7yoIsmSRyphTIGrtN19iSDQYjVQ8b4KZhKOrB1gB9PTQtU60oolopI1rFUJoB4JJ8OPkuu37CjS1povF6iW4y8aCDcfr_yexGvQ17zVknZCN5cahODrasJkUczmLO9LEBXRrQxwb0sYHCv__3xzP9Z-UFWJ-Ax5TNFs-AidlZj892AJofj7Pt3-loosYZfgGPN50t</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype></control><display><type>article</type><title>Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese</source><source>PubMed Central</source><creator>Senoo, Shintaro ; Fujimoto, Masanobu ; Yamaguchi, Yukiko ; Osaki, Mari ; Hanaki, Keiichi ; Namba, Noriyuki</creator><creatorcontrib>Senoo, Shintaro ; Fujimoto, Masanobu ; Yamaguchi, Yukiko ; Osaki, Mari ; Hanaki, Keiichi ; Namba, Noriyuki</creatorcontrib><description>Burosumab, a fully human monoclonal antibody against fibroblast growth factor 23, is mainly administered to patients with severe X-linked hypophosphatemia (XLH). However, there have been few reports on its use in relatively mild cases. In this report, we administered burosumab to two siblings with XLH who had been effectively treated with oral phosphate and active vitamin D. Both patients showed further improvement in radiographic and laboratory findings with burosumab compared with conventional treatment. Upon switching treatment, popliteal pain was reported in case 1 until her phosphorus levels normalized. This emphasizes the importance of monitoring not only rickets and calcium/phosphate metabolism but all symptoms of XLH after initiating burosumab. Notably, in cases 1 and 2, burosumab sustained catch-up growth, especially in case 1, who had not yet reached puberty. Further clinical studies are needed to determine whether burosumab improves growth and proportional abnormalities in patients with mild XLH.</description><identifier>ISSN: 0918-5739</identifier><identifier>EISSN: 1347-7358</identifier><identifier>DOI: 10.1297/cpe.2023-0043</identifier><identifier>PMID: 38299174</identifier><language>eng</language><publisher>Japan: The Japanese Society for Pediatric Endocrinology</publisher><subject>Burosumab ; Case Report ; Fibroblast growth factor 23 ; Rickets ; Rickets severity score ; X-linked hypophosphatemia</subject><ispartof>Clinical Pediatric Endocrinology, 2024, Vol.33(1), pp.27-34</ispartof><rights>2024 by The Japanese Society for Pediatric Endocrinology</rights><rights>2024©The Japanese Society for Pediatric Endocrinology.</rights><rights>2024©The Japanese Society for Pediatric Endocrinology 2024</rights><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10825651/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC10825651/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,1883,4024,27923,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38299174$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Senoo, Shintaro</creatorcontrib><creatorcontrib>Fujimoto, Masanobu</creatorcontrib><creatorcontrib>Yamaguchi, Yukiko</creatorcontrib><creatorcontrib>Osaki, Mari</creatorcontrib><creatorcontrib>Hanaki, Keiichi</creatorcontrib><creatorcontrib>Namba, Noriyuki</creatorcontrib><title>Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia</title><title>Clinical Pediatric Endocrinology</title><addtitle>Clinical Pediatric Endocrinology</addtitle><description>Burosumab, a fully human monoclonal antibody against fibroblast growth factor 23, is mainly administered to patients with severe X-linked hypophosphatemia (XLH). However, there have been few reports on its use in relatively mild cases. In this report, we administered burosumab to two siblings with XLH who had been effectively treated with oral phosphate and active vitamin D. Both patients showed further improvement in radiographic and laboratory findings with burosumab compared with conventional treatment. Upon switching treatment, popliteal pain was reported in case 1 until her phosphorus levels normalized. This emphasizes the importance of monitoring not only rickets and calcium/phosphate metabolism but all symptoms of XLH after initiating burosumab. Notably, in cases 1 and 2, burosumab sustained catch-up growth, especially in case 1, who had not yet reached puberty. Further clinical studies are needed to determine whether burosumab improves growth and proportional abnormalities in patients with mild XLH.</description><subject>Burosumab</subject><subject>Case Report</subject><subject>Fibroblast growth factor 23</subject><subject>Rickets</subject><subject>Rickets severity score</subject><subject>X-linked hypophosphatemia</subject><issn>0918-5739</issn><issn>1347-7358</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><recordid>eNpVkc1u1DAUhS0EokPLki3yC6S1feMkXiE04qdSJRZQqTvL8dxMXJw4sj1Tzdvj6cAAG9vS_c6xzj2EvOPsmgvV3tgFrwUTUDFWwwuy4lC3VQuye0lWTPGuki2oC_ImpUfGhGINe00uoBNK8bZekf33J5ft6OYtzYH2uxjSbjI9HWKYqA3zHufswmw8zSNGsxyom2lyvS-KRIt2pBG9yW6P_kCf0PuqqHIM3uOGPlSF-1ke42EJyxjSMpqMkzNX5NVgfMK3v-9Lcv_504_11-ru25fb9ce7yoIsmSRyphTIGrtN19iSDQYjVQ8b4KZhKOrB1gB9PTQtU60oolopI1rFUJoB4JJ8OPkuu37CjS1povF6iW4y8aCDcfr_yexGvQ17zVknZCN5cahODrasJkUczmLO9LEBXRrQxwb0sYHCv__3xzP9Z-UFWJ-Ax5TNFs-AidlZj892AJofj7Pt3-loosYZfgGPN50t</recordid><startdate>2024</startdate><enddate>2024</enddate><creator>Senoo, Shintaro</creator><creator>Fujimoto, Masanobu</creator><creator>Yamaguchi, Yukiko</creator><creator>Osaki, Mari</creator><creator>Hanaki, Keiichi</creator><creator>Namba, Noriyuki</creator><general>The Japanese Society for Pediatric Endocrinology</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>5PM</scope></search><sort><creationdate>2024</creationdate><title>Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia</title><author>Senoo, Shintaro ; Fujimoto, Masanobu ; Yamaguchi, Yukiko ; Osaki, Mari ; Hanaki, Keiichi ; Namba, Noriyuki</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3523-5e1099354e8d86c1343fa59b3d31a60e24fc433b4f670972352499a2790e5af33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Burosumab</topic><topic>Case Report</topic><topic>Fibroblast growth factor 23</topic><topic>Rickets</topic><topic>Rickets severity score</topic><topic>X-linked hypophosphatemia</topic><toplevel>online_resources</toplevel><creatorcontrib>Senoo, Shintaro</creatorcontrib><creatorcontrib>Fujimoto, Masanobu</creatorcontrib><creatorcontrib>Yamaguchi, Yukiko</creatorcontrib><creatorcontrib>Osaki, Mari</creatorcontrib><creatorcontrib>Hanaki, Keiichi</creatorcontrib><creatorcontrib>Namba, Noriyuki</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Clinical Pediatric Endocrinology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Senoo, Shintaro</au><au>Fujimoto, Masanobu</au><au>Yamaguchi, Yukiko</au><au>Osaki, Mari</au><au>Hanaki, Keiichi</au><au>Namba, Noriyuki</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia</atitle><jtitle>Clinical Pediatric Endocrinology</jtitle><addtitle>Clinical Pediatric Endocrinology</addtitle><date>2024</date><risdate>2024</risdate><volume>33</volume><issue>1</issue><spage>27</spage><epage>34</epage><pages>27-34</pages><artnum>2023-0043</artnum><issn>0918-5739</issn><eissn>1347-7358</eissn><abstract>Burosumab, a fully human monoclonal antibody against fibroblast growth factor 23, is mainly administered to patients with severe X-linked hypophosphatemia (XLH). However, there have been few reports on its use in relatively mild cases. In this report, we administered burosumab to two siblings with XLH who had been effectively treated with oral phosphate and active vitamin D. Both patients showed further improvement in radiographic and laboratory findings with burosumab compared with conventional treatment. Upon switching treatment, popliteal pain was reported in case 1 until her phosphorus levels normalized. This emphasizes the importance of monitoring not only rickets and calcium/phosphate metabolism but all symptoms of XLH after initiating burosumab. Notably, in cases 1 and 2, burosumab sustained catch-up growth, especially in case 1, who had not yet reached puberty. Further clinical studies are needed to determine whether burosumab improves growth and proportional abnormalities in patients with mild XLH.</abstract><cop>Japan</cop><pub>The Japanese Society for Pediatric Endocrinology</pub><pmid>38299174</pmid><doi>10.1297/cpe.2023-0043</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0918-5739 |
ispartof | Clinical Pediatric Endocrinology, 2024, Vol.33(1), pp.27-34 |
issn | 0918-5739 1347-7358 |
language | eng |
recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_10825651 |
source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; J-STAGE (Japan Science & Technology Information Aggregator, Electronic) Freely Available Titles - Japanese; PubMed Central |
subjects | Burosumab Case Report Fibroblast growth factor 23 Rickets Rickets severity score X-linked hypophosphatemia |
title | Switching to burosumab from conventional therapy in siblings with relatively well-controlled X-linked hypophosphatemia |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-25T17%3A04%3A23IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-pubmed_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Switching%20to%20burosumab%20from%20conventional%20therapy%20in%20siblings%20with%20relatively%20well-controlled%20X-linked%20hypophosphatemia&rft.jtitle=Clinical%20Pediatric%20Endocrinology&rft.au=Senoo,%20Shintaro&rft.date=2024&rft.volume=33&rft.issue=1&rft.spage=27&rft.epage=34&rft.pages=27-34&rft.artnum=2023-0043&rft.issn=0918-5739&rft.eissn=1347-7358&rft_id=info:doi/10.1297/cpe.2023-0043&rft_dat=%3Cpubmed_cross%3E38299174%3C/pubmed_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/38299174&rfr_iscdi=true |